Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy

Kim, Amy Hyein; Jang, Jung Eun; Han, Jin

doi:10.1016/j.biopha.2021.112463

Cited by 24 publications

(16 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, the use of new medications and combination therapies for glycemic control in T2D is rapidly evolving ( Ceylan-Isik et al., 2008 ; Kashiwagi et al., 2021 ; Kessler et al., 2021 ; Oh et al., 2021 ; Tadic et al., 2021 ; Kim et al., 2022 ). As patients with T2D often have other risk factors, including obesity, hypertension, dyslipidemia, and renal disease, current treatment strategies favor combination therapies, such as anti-hyperglycemic and anti-hypertensive therapy, to retard the progression of HFpEF.…”

Section: Treatment Options For Hfpef In T2dmentioning

confidence: 99%

Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics

Abudureyimu

Luo

Wang

et al. 2022

Journal of Molecular Cell Biology

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2D) is a devastating metabolic abnormality featured by insulin resistance, hyperglycemia, and hyperlipidemia. T2D provokes unique metabolic changes and compromises cardiovascular geometry and function. Meanwhile, T2D increases the overall risk for heart failure (HF) and acts independent of classical risk factors including coronary artery disease, hypertension, and valvular heart diseases. The incidence of HF is extremely high in patients with T2D and is manifested as heart failure with preserved, reduced, and midrange ejection fraction (HFpEF, HFrEF, and HFmrEF, respectively), all of which significantly worsen the prognosis for T2D. HFpEF is seen in approximately half of HF cases and is defined as a heterogenous syndrome with discrete phenotypes, in particularly in close association with metabolic syndrome. Nonetheless, management of HFpEF in T2D remains unclear, largely due to the poorly defined pathophysiology behind HFpEF. Here, in this review, we will summarize findings from multiple preclinical and clinical studies as well as recent clinical trials, mainly focusing on the pathophysiology, potential mechanisms, and therapies of HFpEF in T2D.

show abstract

Section: Treatment Options For Hfpef In T2dmentioning

confidence: 99%

Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics

Abudureyimu

Luo

Wang

et al. 2022

Journal of Molecular Cell Biology

View full text Add to dashboard Cite

show abstract

“…The occurrence of DR is, therefore, an independent predictor of heart failure. The identification of selected biomarkers integrating these processes is of great importance in order to detect, prevent, or even treat diabetes-associated heart failure at an early stage once it has been established [ 99 ].…”

Section: Eyes Renal and Cardiac Microvasculature—from A Microvascular...mentioning

confidence: 99%

The Protective Effects of Neurotrophins and MicroRNA in Diabetic Retinopathy, Nephropathy and Heart Failure via Regulating Endothelial Function

Shityakov¹,

Nagai

Ergün

et al. 2022

Biomolecules

View full text Add to dashboard Cite

Diabetes mellitus is a common disease affecting more than 537 million adults worldwide. The microvascular complications that occur during the course of the disease are widespread and affect a variety of organ systems in the body. Diabetic retinopathy is one of the most common long-term complications, which include, amongst others, endothelial dysfunction, and thus, alterations in the blood-retinal barrier (BRB). This particularly restrictive physiological barrier is important for maintaining the neuroretina as a privileged site in the body by controlling the inflow and outflow of fluid, nutrients, metabolic end products, ions, and proteins. In addition, people with diabetic retinopathy (DR) have been shown to be at increased risk for systemic vascular complications, including subclinical and clinical stroke, coronary heart disease, heart failure, and nephropathy. DR is, therefore, considered an independent predictor of heart failure. In the present review, the effects of diabetes on the retina, heart, and kidneys are described. In addition, a putative common microRNA signature in diabetic retinopathy, nephropathy, and heart failure is discussed, which may be used in the future as a biomarker to better monitor disease progression. Finally, the use of miRNA, targeted neurotrophin delivery, and nanoparticles as novel therapeutic strategies is highlighted.

show abstract

“…The development and progression of DCM were associated with inflammation; mitochondrial dysfunction; oxidative stress; impaired cardiac insulin signalling and calcium metabolism; microvascular dysfunction; endoplasmic reticulum stress; endothelial dysfunction; cell death and number of other pathologic conditions [ 7 , 8 , 9 , 10 ]. Comparing all DM complications, DM patients have a two-fold greater risk of developing heart failure with DCM accounting for nearly 80% of mortality cases [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

The Role of Mitochondrial Abnormalities in Diabetic Cardiomyopathy

Dabravolski

Sadykhov

Kartuesov

et al. 2022

IJMS

View full text Add to dashboard Cite

Diabetic cardiomyopathy (DCM) is defined as the presence in diabetic patients of abnormal cardiac structure and performance (such as left ventricular hypertrophy, fibrosis, and arrhythmia) in the absence of other cardiac risk factors (such as hypertension or coronary artery disease). Although the pathogenesis of DCM remains unclear currently, mitochondrial structural and functional dysfunctions are recognised as a central player in the DCM development. In this review, we focus on the role of mitochondrial dynamics, biogenesis and mitophagy, Ca2+ metabolism and bioenergetics in the DCM development and progression. Based on the crucial role of mitochondria in DCM, application of mitochondria-targeting therapies could be effective strategies to slow down the progression of the disease.

show abstract

Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy

Cited by 24 publications

References 52 publications

Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics

Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics

The Protective Effects of Neurotrophins and MicroRNA in Diabetic Retinopathy, Nephropathy and Heart Failure via Regulating Endothelial Function

The Role of Mitochondrial Abnormalities in Diabetic Cardiomyopathy

Contact Info

Product

Resources

About